BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 17644735)

  • 1. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Leone G; Foà R; Larocca LM
    Blood; 2007 Nov; 110(9):3384-6. PubMed ID: 17644735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Straightforward identification of masked polycythemia vera based on proposed revision of World Health Organization diagnostic criteria for BCR-ABL1-negative myeloproliferative neoplasms.
    Chu D; Cho YU; Jang S; Seo EJ; Park CJ
    Ann Lab Med; 2015 Nov; 35(6):651-3. PubMed ID: 26354357
    [No Abstract]   [Full Text] [Related]  

  • 8. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A
    Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].
    Krähling T; Balassa K; Meggyesi N; Bors A; Csomor J; Bátai Á; Halm G; Egyed M; Fekete S; Reményi P; Masszi T; Tordai A; Andrikovics H
    Orv Hetil; 2014 Dec; 155(52):2074-81. PubMed ID: 25528320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular genetic evaluation of myeloproliferative neoplasms.
    Azzato EM; Bagg A
    Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.
    Hsu HC
    J Chin Med Assoc; 2007 Mar; 70(3):89-93. PubMed ID: 17389152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of JAK2 V617F, CALR, and MPL Mutations as Molecular Diagnostic Markers of Myeloproliferative Neoplasms in Kurdish Patients. A Single-center Experience.
    Basim Najm M; Jalal SD; Getta HA
    Cell Mol Biol (Noisy-le-grand); 2022 Aug; 68(8):202-209. PubMed ID: 36800830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Barbui T; Thiele J; Vannucchi AM; Tefferi A
    Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MPL W515L mutation in Chinese patients with myeloproliferative diseases.
    Xu W; Li JY; Xia J; Zhang SJ; Fan L; Qiao C
    Leuk Lymphoma; 2008 May; 49(5):955-8. PubMed ID: 18464114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms.
    Lieu CH; Shen YJ; Lai WC; Tsai WH; Hsu HC
    J Chin Med Assoc; 2010 Oct; 73(10):530-2. PubMed ID: 21051030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.
    Spivak JL; Merchant A; Williams DM; Rogers O; Zhao W; Duffield A; Resar LS; Moliterno AR; Zhao ZJ
    PLoS One; 2020; 15(6):e0232801. PubMed ID: 32479500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.
    Vainchenker W; Constantinescu SN
    Hematology Am Soc Hematol Educ Program; 2005; ():195-200. PubMed ID: 16304380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
    Mesa R; Jamieson C; Bhatia R; Deininger MW; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; Klisovic RB; Kropf P; Mohan SR; Oh S; Padron E; Podoltsev N; Pollyea DA; Rampal R; Rein LA; Scott B; Snyder DS; Stein BL; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; Sundar H
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1572-1611. PubMed ID: 27956542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.